By 23andMe Co-Founders Linda Avey and Anne Wojcicki
We started 23andMe with a simple, yet expansive, vision: to take DNA into the mainstream. In order to demystify genetics, we thought the best approach was to give individuals access to their genomes and help them gain personalized insight into their own unique code. This was our premise when we launched a year and a half ago. We now have
an expanding community of individuals, armed with their genetic profiles, who are the early adopters of what we believe will become standard practice — having ready access to vitally important information.
We’re now moving into the next phase of our mission: to provide a wholly new research platform that enables our online community to voluntarily participate in unprecedented genetic studies. Our approach is new because it leverages the web to bring people together from all over the globe who are willing to share information about their own health experiences (phenotype), which is then combined with their genetic profile (genotype). This combination, genotype + phenotype, is the same formula that drives genome-wide association studies (GWAS). But ours is a community-centric model that also delivers on-going, valuable feedback to each member.
Scientists have only recently had the ability to conduct GWAS, owing to tremendous advances in the technology platforms that generate the data, as well as spectacular decreases in the cost. These studies are now yielding compelling results in the examination of many common diseases and are chipping away at the elusive genetic components of conditions such as type 2 diabetes, heart disease and many of the cancers. These diseases aren’t like single gene disorders (such as Tay-Sachs, cystic fibrosis and sickle cell anemia) in which the genetic story is straightforward. Most common diseases have complicated genetic as well as environmental components, and teasing out these factors is painstakingly difficult. This also holds true for the study of genes and drug response (pharmacogenetics), the holy grail of personalized medicine.
One of the biggest challenges in conducting GWAS is identifying large enough cohorts of people with a disease or trait, and then being able to categorize the details of their symptoms and progression. Combine this with the complexity of multiple genetic factors, each with a relatively small effect but somehow working in concert, and it becomes maddeningly difficult to put two and two together. This is why these studies require very large numbers of enrolled individuals, to achieve the statistical power required to make any headway. If researchers are limited to a defined geographic region in which to recruit patients, they often can’t reach the bar. This often leads to consortia-based projects, where multiple clinical centers combine resources. The problem with this model is the lack of continuity between the groups, not to mention the power struggles that often ensue: Who writes the grant? Which lab runs the samples? Who controls the rights to the data? Which institute files and maintains the patents? Who is the lead author on the publication?
Our goal is to greatly simplify the entire process. By centralizing the recruitment of individuals, the lab work and the collection of phenotypic data, we believe we’ll be able to move beyond traditional hurdles and take GWAS to a whole new level that we’re calling Research 2.0. We think the study of human disease and drug response deserves the application of 21st century technology, including the use of social networking tools proving so effective in web-based sharing of information à la Facebook and YouTube.
So today we are announcing the first of many studies we plan to undertake. Parkinson’s disease has all the elements described above: complicated genetics, hints of environmental triggers, varying rates of progression, differing drug response. We’re excited, and gratified, to have Sergey Brin’s support, as well as the cooperation of The Parkinson’s Institute and The Michael J. Fox Foundation, in jump-starting the world’s largest study of this disease — involving 10,000 individuals with PD. Please visit our Parkinson’s Community for more information on this ground-breaking project.
This is just the beginning of our mission to establish a new paradigm that changes the face of research, and focuses on the people rather than the process.